<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03254108</url>
  </required_header>
  <id_info>
    <org_study_id>263-102-00001</org_study_id>
    <nct_id>NCT03254108</nct_id>
  </id_info>
  <brief_title>Clinical Pharmacology Trial to Investigate the Dose of OPC-61815 Injection Equivalent to Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure</brief_title>
  <official_title>A Multicenter, Double-blind, Randomized, Active-controlled, Parallel-group Comparison Clinical Pharmacology Trial to Investigate the Dose of OPC-61815 Injection Equivalent to Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The dose for intravenous administration of OPC-61815 achieving tolvaptan exposure equivalent
      to that for oral administration of tolvaptan 15-mg tablet will be investigated by
      administering OPC-61815 injection 2 to 16mg or tolvaptan 15-mg oral tablet to subjects with
      congestive heart failure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2017</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax on Day 1 of the treatment period</measure>
    <time_frame>Baseline, 1, 1.5, 2, 4, 6, 12 24 hours after the start of administration of investigational drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC24h on Day1 of the treatment period</measure>
    <time_frame>Baseline, 1, 1.5, 2, 4, 6, 12 24 hours after the start of administration of investigational drug</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>OPC-61815 injection 2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 2 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPC-61815 injection 4mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 4 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPC-61815 injection 8mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 8 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPC-61815 injection 16mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tolvaptan tablet 15mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC-61815 injection 2mg</intervention_name>
    <description>Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 2 mg.</description>
    <arm_group_label>OPC-61815 injection 2mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC-61815 injection 4mg</intervention_name>
    <description>Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 4 mg.</description>
    <arm_group_label>OPC-61815 injection 4mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC-61815 injection 8mg</intervention_name>
    <description>Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 8 mg.</description>
    <arm_group_label>OPC-61815 injection 8mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC-61815 injection 16mg</intervention_name>
    <description>Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg.</description>
    <arm_group_label>OPC-61815 injection 16mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolvaptan tablet 15mg</intervention_name>
    <description>Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo.</description>
    <arm_group_label>Tolvaptan tablet 15mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who are currently on treatment with any of the following diuretics

               -  Loop diuretics equivalent to furosemide tablet or fine granules at a dose of 40
                  mg/day or higher

               -  Concomitant use of a loop diuretic and a thiazide diuretic (including thiazide
                  analogs) at any dose

               -  Concomitant use of a loop diuretic and an aldosterone antagonist or
                  potassium-sparing diuretic agent at any dose

          2. Subjects with congestive heart failure in whom lower limb edema, pulmonary congestion,
             and/or jugular venous distension due to volume overload is present

          3. Subjects who are currently hospitalized or who are able to be hospitalized during the
             trial

        Exclusion Criteria:

          1. Subjects with acute heart failure

          2. Subjects with a history of hypersensitivity to any of ingredients of OPC-61815 or
             tolvaptan

          3. Subjects who are unable to sense thirst or who have difficulty with fluid intake
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroaki Ono</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Drug Information Center</last_name>
    <phone>+81-3-6361-7314</phone>
    <email>koidet@otsuka.jp</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Kanto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2017</study_first_submitted>
  <study_first_submitted_qc>August 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2017</study_first_posted>
  <last_update_submitted>November 19, 2017</last_update_submitted>
  <last_update_submitted_qc>November 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolvaptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

